Compare MakeMyTrip Ltd (MMYT) vs Summit Therapeutics Inc (SMMT) Price & Performance

MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal despite recent weakness. The company shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.25 beating expectations of $0.17. Revenue reached $978.34 million in 2025 with a 73.77% gross margin, though 2026 projections indicate margin compression. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target.

The stock presents a growth opportunity with strong operational performance but faces risks from travel disruptions and rising debt levels. While current valuation metrics appear elevated (P/E 147.78), the company's market leadership in Indian online travel and consistent execution support the bullish case. Key risks include competitive pressures and macroeconomic sensitivity to travel demand.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.